In this study, we found that high frequencies of circulating Treg cells one week after anti-PD-1 immunotherapy in patients with advanced NSCLC were associated with prolonged PFS, OS, and durable clinical benefit when compared with patients with a low frequency of Treg cells, which is consistent with previous results. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.